Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Donate
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
When Care(giving) Meet...
Live, educational event for the community around Greenville, SC.
/Events/MSF-Events/2019/One-Time-Events/When-Care(giving)-Meets-Love-(2)
Assistive Technology P...
The Assistive Technology Program provides information about, and funding for, devices that help...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
Study: Early lesions point to future secondary progressive MS
November 18, 2019
A recent study set out to determine the long-term clinical outcomes in MS, and to identify early prognostic features of these outcomes. The findings suggest infratentorial lesions and deep white matter lesions at year one were the strongest early predictors of secondary progressive MS at 30 years.
132 people presenting with a clinically isolated syndrome were recruited by researchers in the UK, Netherlands, and Spain between 1984 and 1987, and followed up clinically and radiologically one, five, 10, 14, 20 and 30 years later. All available notes and MRI scans were reviewed. MS was defined according to the 2010 McDonald criteria.
Clinical outcome data was obtained in 120 participants at 30 years old. Eighty were known to have developed MS the age of 30. Expanded disability status scale scores were available in 107 participants, of whom 77 had MS: 42 percent remained fully ambulatory, all of whom had relapsing-remitting MS; 4 percent had relapsing MS with an EDSS score of greater than 3.5; 34 percent had secondary progressive MS, all of whom had EDSS score of greater than 3.5; and MS contributed to death in 20 percent. Of those with MS, 11 have been treated with a DMT.
The researchers found the strongest early predictors (within five years of presentation) of secondary progressive MS at 30 years were presence of baseline infratentorial (the region of the brain that contains the cerebellum) lesions and deep white matter lesions at one year.
Thirty years after onset, in a largely untreated cohort, there was a divergence of MS outcomes; some people accrued substantial disability early on, while others ran a more favorable long-term course. These outcomes could, in part, be predicted by radiological findings from within a year of first presentation.
The findings were published in the
Annals of Neurology
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more
Study uncovers potential risks of common MS treatment
Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more